{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:19:05Z","timestamp":1791433145209,"version":"4.3.3"},"reference-count":204,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s10787-023-01259-0","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T06:02:10Z","timestamp":1686808930000},"page":"1605-1627","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Neuromodulation in Parkinson\u2019s disease targeting opioid and cannabinoid receptors, understanding the role of NLRP3 pathway: a novel therapeutic approach"],"prefix":"10.1007","volume":"31","author":[{"given":"Md Reyaz","family":"Alam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2780-6632","authenticated-orcid":false,"given":"Shamsher","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"key":"1259_CR1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/107628004773933299","volume":"10","author":"K Abascal","year":"2004","unstructured":"Abascal K, Yarnell E (2004) Alzheimer\u2019s disease: part 2\u2014a botanical treatment plan. Altern Complement Ther 10:67\u201372","journal-title":"Altern Complement Ther"},{"key":"1259_CR2","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1038\/466S6a","volume":"466","author":"A Abbott","year":"2010","unstructured":"Abbott A (2010) Levodopa: the story so far. Nature 466:S6\u2013S7","journal-title":"Nature"},{"key":"1259_CR3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/0166-2236(85)90012-8","volume":"8","author":"Y Agid","year":"1985","unstructured":"Agid Y, Javoy-Agid F (1985) Peptides and Parkinson\u2019s disease. Trends Neurosci 8:30\u201335","journal-title":"Trends Neurosci"},{"key":"1259_CR4","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1523\/JNEUROSCI.3101-05.2006","volume":"26","author":"T Aguado","year":"2006","unstructured":"Aguado T, Palazuelos J, Monory K, Stella N, Cravatt B, Lutz B, Marsicano G, Kokaia Z, Guzm\u00e1n M, Galve-Roperh I (2006) The endocannabinoid system promotes astroglial differentiation by acting on neural progenitor cells. J Neurosci 26:1551\u20131561","journal-title":"J Neurosci"},{"key":"1259_CR5","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.3390\/ph3061949","volume":"3","author":"MA Ajmone-Cat","year":"2010","unstructured":"Ajmone-Cat MA, Bernardo A, Greco A, Minghetti L (2010) Non-steroidal anti-inflammatory drugs and brain inflammation: effects on microglial functions. Pharmaceuticals 3:1949\u20131965","journal-title":"Pharmaceuticals"},{"key":"1259_CR6","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/0166-2236(90)90107-L","volume":"13","author":"GE Alexander","year":"1990","unstructured":"Alexander GE, Crutcher MD (1990) Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 13:266\u2013271","journal-title":"Trends Neurosci"},{"key":"1259_CR7","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1146\/annurev.ne.09.030186.002041","volume":"9","author":"GE Alexander","year":"1986","unstructured":"Alexander GE, Delong MR, Strick PL (1986) Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 9:357\u2013381","journal-title":"Annu Rev Neurosci"},{"key":"1259_CR8","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1007\/s12035-018-1109-6","volume":"56","author":"AE-E Aly","year":"2019","unstructured":"Aly AE-E, Harmon BT, Padegimas L, Sesenoglu-Laird O, Cooper MJ, Waszczak BL (2019) Intranasal delivery of pGDNF DNA nanoparticles provides neuroprotection in the Rat 6-hydroxydopamine model of Parkinson\u2019s disease. Mol Neurobiol 56:688\u2013701","journal-title":"Mol Neurobiol"},{"key":"1259_CR9","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/bph.14123","volume":"175","author":"L Arcuri","year":"2018","unstructured":"Arcuri L, Novello S, Frassineti M, Mercatelli D, Pisan\u00f2 CA, Morella I, Fasano S, Journigan BV, Meyer ME, Polgar WE (2018) Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin\/orphanin FQ receptor agonists. Br J Pharmacol 175:782\u2013796","journal-title":"Br J Pharmacol"},{"key":"1259_CR10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3233\/JPD-181331","volume":"8","author":"TM Axelsen","year":"2018","unstructured":"Axelsen TM, Woldbye DP (2018) Gene therapy for Parkinson\u2019s disease, an update. J Parkinsons Dis 8:195\u2013215","journal-title":"J Parkinsons Dis"},{"key":"1259_CR11","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/mnfr.200900516","volume":"54","author":"S Banni","year":"2010","unstructured":"Banni S, Di Marzo V (2010) Effect of dietary fat on endocannabinoids and related mediators: consequences on energy homeostasis, inflammation and mood. Mol Nutr Food Res 54:82\u201392","journal-title":"Mol Nutr Food Res"},{"key":"1259_CR12","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/mt.2013.281","volume":"22","author":"RT Bartus","year":"2014","unstructured":"Bartus RT, Weinberg MS, Samulski RJ (2014) Parkinson\u2019s disease gene therapy: success by design meets failure by efficacy. Mol Ther 22:487\u2013497","journal-title":"Mol Ther"},{"key":"1259_CR13","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.brainresbull.2019.01.016","volume":"146","author":"HS Baul","year":"2019","unstructured":"Baul HS, Manikandan C, Sen D (2019) Cannabinoid receptor as a potential therapeutic target for Parkinson\u2019s disease. Brain Res Bull 146:244\u2013252","journal-title":"Brain Res Bull"},{"key":"1259_CR14","doi-asserted-by":"crossref","first-page":"5114","DOI":"10.3390\/ijms23095114","volume":"23","author":"A Bedini","year":"2022","unstructured":"Bedini A, Cuna E, Baiula M, Spampinato S (2022) Quantitative systems pharmacology and biased agonism at opioid receptors: a potential avenue for improved analgesics. Int J Mol Sci 23:5114","journal-title":"Int J Mol Sci"},{"key":"1259_CR15","doi-asserted-by":"crossref","first-page":"6235","DOI":"10.3390\/ijms21176235","volume":"21","author":"T Behl","year":"2020","unstructured":"Behl T, Kaur G, Bungau S, Jhanji R, Kumar A, Mehta V, Zengin G, Brata R, Hassan SSU, Fratila O (2020) Distinctive evidence involved in the role of endocannabinoid signalling in parkinson\u2019s disease: a perspective on associated therapeutic interventions. Int J Mol Sci 21:6235","journal-title":"Int J Mol Sci"},{"key":"1259_CR16","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/266556a0","volume":"266","author":"JD Belluzzi","year":"1977","unstructured":"Belluzzi JD, Stein L (1977) Enkephalin may mediate euphoria and drive-reduction reward. Nature 266:556\u2013558","journal-title":"Nature"},{"key":"1259_CR17","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1212\/WNL.0b013e3182662098","volume":"79","author":"EE Benarroch","year":"2012","unstructured":"Benarroch EE (2012) Endogenous opioid systems: current concepts and clinical correlations. Neurology 79:807\u2013814","journal-title":"Neurology"},{"key":"1259_CR18","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/35086062","volume":"2","author":"E Bezard","year":"2001","unstructured":"Bezard E, Brotchie JM, Gross CE (2001a) Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2:577\u2013588","journal-title":"Nat Rev Neurosci"},{"key":"1259_CR19","first-page":"1092","volume":"15","author":"E Bezard","year":"2001","unstructured":"Bezard E, Crossman AR, Gross CE, Brotchie JM (2001b) Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson\u2019s disease. FASEB J 15:1092\u20131094","journal-title":"FASEB J"},{"key":"1259_CR20","doi-asserted-by":"crossref","first-page":"6812","DOI":"10.1523\/JNEUROSCI.0610-20.2020","volume":"40","author":"E Bezard","year":"2020","unstructured":"Bezard E, Li Q, Hulme H, Fridjonsdottir E, Nilsson A, Pioli E, Andren PE, Crossman AR (2020) \u00b5 opioid receptor agonism for L-Dopa-induced dyskinesia In Parkinson\u2019s disease. J Neurosci 40:6812\u20136819","journal-title":"J Neurosci"},{"key":"1259_CR21","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jconrel.2022.02.005","volume":"343","author":"G Bhattacharjee","year":"2022","unstructured":"Bhattacharjee G, Gohil N, Khambhati K, Mani I, Maurya R, Karapurkar JK, Gohil J, Chu D-T, Vu-Thi H, Alzahrani KJ (2022) Current approaches in Crispr-Cas9 mediated gene editing for biomedical and therapeutic applications. J Control Release 343:703\u2013723","journal-title":"J Control Release"},{"key":"1259_CR22","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1515\/REVNEURO.2003.14.3.285","volume":"14","author":"A Binaschi","year":"2003","unstructured":"Binaschi A, Bregola G, Simonato M (2003) On the role of somatostatin in seizure control: clues from the hippocampus. Rev Neurosci 14:285\u2013301","journal-title":"Rev Neurosci"},{"key":"1259_CR23","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/00001756-200004070-00005","volume":"11","author":"CV Borlongan","year":"2000","unstructured":"Borlongan CV, Su T-P, Wang Y (2000) Treatment with delta opioid peptide enhances in vitro and in vivo survival of rat dopaminergic neurons. NeuroReport 11:923\u2013926","journal-title":"NeuroReport"},{"key":"1259_CR24","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3727\/000000001783987007","volume":"10","author":"CV Borlongan","year":"2001","unstructured":"Borlongan CV, Su T-P, Wang Y (2001) Delta opioid peptide augments functional effects and intrastriatal graft survival of rat fetal ventral mesencephalic cells. Cell Transplant 10:53\u201358","journal-title":"Cell Transplant"},{"key":"1259_CR25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3233\/JPD-201981","volume":"11","author":"M Borsche","year":"2021","unstructured":"Borsche M, Pereira SL, Klein C, Gr\u00fcnewald A (2021) Mitochondria and Parkinson\u2019s disease: clinical, molecular, and translational aspects. J Parkinsons Dis 11:45\u201360","journal-title":"J Parkinsons Dis"},{"key":"1259_CR26","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1161\/STROKEAHA.116.014793","volume":"48","author":"I Bravo-Ferrer","year":"2017","unstructured":"Bravo-Ferrer I, Cuartero MI, Zarruk JG, Pradillo JM, Hurtado O, Romera VG, D\u00edaz-Alonso J, Garc\u00eda-Segura JM, Guzm\u00e1n M, Lizasoain I (2017) Cannabinoid Type-2 receptor drives neurogenesis and improves functional outcome after stroke. Stroke 48:204\u2013212","journal-title":"Stroke"},{"key":"1259_CR27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0197-4580(81)90033-6","volume":"2","author":"SH Buck","year":"1981","unstructured":"Buck SH, Deshmukh PP, Burks TF, Yamamura HI (1981) A survey of substance P, somatostatin, and neurotensin levels in aging in the rat and human central nervous system. Neurobiol Aging 2:257\u2013264","journal-title":"Neurobiol Aging"},{"key":"1259_CR28","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.neulet.2018.12.017","volume":"696","author":"MEB Bueno","year":"2019","unstructured":"Bueno MEB, Do Nascimento Neto LI, Terra MB, Barboza NM, Okano AH, Smaili SM (2019) Effectiveness of acute transcranial direct current stimulation on non-motor and motor symptoms in Parkinson\u2019s disease. Neurosci Lett 696:46\u201351","journal-title":"Neurosci Lett"},{"key":"1259_CR29","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12017-012-8180-3","volume":"14","author":"Z Cai","year":"2012","unstructured":"Cai Z, Ratka A (2012) Opioid system and Alzheimer\u2019s disease. NeuroMol Med 14:91\u2013111","journal-title":"NeuroMol Med"},{"key":"1259_CR30","doi-asserted-by":"crossref","first-page":"S570","DOI":"10.1002\/mds.22019","volume":"23","author":"P Calabresi","year":"2008","unstructured":"Calabresi P, Di Filippo M, Ghiglieri V, Picconi B (2008) Molecular mechanisms underlying levodopa-induced dyskinesia. Mov Disord 23:S570\u2013S579","journal-title":"Mov Disord"},{"key":"1259_CR31","first-page":"S70","volume":"47","author":"F Calon","year":"2000","unstructured":"Calon F, Grondin R, Morissette M, Goulet M, Blanchet PJ, Di Paolo T, Bedard P (2000a) Molecular basis of levodopa-induced dyskinesias. Ann Neurol 47:S70","journal-title":"Ann Neurol"},{"key":"1259_CR32","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1016\/S1471-1931(00)00026-4","volume":"23","author":"F Calon","year":"2000","unstructured":"Calon F, Tahar AH, Blanchet PJ, Morissette M, Grondin R, Goulet M, Doucet J-P, Robertson GS, Nestler E, Di Paolo T (2000b) Dopamine-receptor stimulation: biobehavioural and biochemical consequences. Trends Neurosci 23:S92\u2013S100","journal-title":"Trends Neurosci"},{"key":"1259_CR33","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/jnen\/61.2.186","volume":"61","author":"F Calon","year":"2002","unstructured":"Calon F, Birdi S, Rajput AH, Hornykiewicz O, B\u00e9dard PJ, Di Paolo T (2002) Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias. J Neuropathol Exp Neurol 61:186\u2013196","journal-title":"J Neuropathol Exp Neurol"},{"key":"1259_CR34","doi-asserted-by":"crossref","first-page":"6517","DOI":"10.3390\/ijms22126517","volume":"22","author":"A Cardinale","year":"2021","unstructured":"Cardinale A, Calabrese V, De Iure A, Picconi B (2021) Alpha-synuclein as a prominent actor in the inflammatory synaptopathy of Parkinson\u2019s disease. Int J Mol Sci 22:6517","journal-title":"Int J Mol Sci"},{"key":"1259_CR35","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/1801200a0","volume":"180","author":"A Carlsson","year":"1957","unstructured":"Carlsson A, Lindqvist M, Magnusson T (1957) 3, 4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180:1200\u20131200","journal-title":"Nature"},{"key":"1259_CR36","first-page":"264","volume-title":"The neuropharmacological basis of reward","author":"GD Carr","year":"1989","unstructured":"Carr GD, Fibiger HC, Phillips AG (1989) Conditioned place preference as a measure of drug reward. In: Liebman JM, Cooper SJ (eds) The neuropharmacological basis of reward, pp 264\u2013319"},{"key":"1259_CR37","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1212\/01.WNL.0000140288.48796.8E","volume":"63","author":"C Carroll","year":"2004","unstructured":"Carroll C, Bain P, Teare L, Liu X, Joint C, Wroath C, Parkin S, Fox P, Wright D, Hobart J (2004) Cannabis for dyskinesia in parkinson disease: a randomized double-blind crossover study. Neurology 63:1245\u20131250","journal-title":"Neurology"},{"key":"1259_CR38","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.expneurol.2014.02.022","volume":"255","author":"T Chen","year":"2014","unstructured":"Chen T, Li J, Chao D, Sandhu HK, Liao X, Zhao J, Wen G, Xia Y (2014) \u03b4-opioid receptor activation reduces \u03b1-synuclein overexpression and oligomer formation induced by MPP+ and\/or hypoxia. Exp Neurol 255:127\u2013136","journal-title":"Exp Neurol"},{"key":"1259_CR39","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12974-022-02419-9","volume":"19","author":"K-P Chen","year":"2022","unstructured":"Chen K-P, Hua K-F, Tsai F-T, Lin T-Y, Cheng C-Y, Yang D-I, Hsu H-T, Ju T-C (2022) A selective inhibitor of the Nlrp3 inflammasome as a potential therapeutic approach for neuroprotection in a transgenic mouse model of Huntington\u2019s disease. J Neuroinflammation 19:56","journal-title":"J Neuroinflammation"},{"key":"1259_CR40","doi-asserted-by":"crossref","first-page":"6508","DOI":"10.4049\/jimmunol.1102435","volume":"187","author":"YC Chung","year":"2011","unstructured":"Chung YC, Bok E, Huh SH, Park J-Y, Yoon S-H, Kim SR, Kim Y-S, Maeng S, Park SH, Jin BK (2011) Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation. J Immunol 187:6508\u20136517","journal-title":"J Immunol"},{"key":"1259_CR41","doi-asserted-by":"crossref","first-page":"E54271","DOI":"10.1371\/journal.pone.0054271","volume":"8","author":"C Compagnucci","year":"2013","unstructured":"Compagnucci C, Di Siena S, Bustamante MB, Di Giacomo D, Di Tommaso M, Maccarrone M, Grimaldi P, Sette C (2013) Type-1 (Cb1) cannabinoid receptor promotes neuronal differentiation and maturation of neural stem cells. PLoS ONE 8:E54271","journal-title":"PLoS ONE"},{"key":"1259_CR42","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.1007\/s12035-020-02054-6","volume":"57","author":"R Cooray","year":"2020","unstructured":"Cooray R, Gupta V, Suphioglu C (2020) Current aspects of the endocannabinoid system and targeted THC and CBD phytocannabinoids as potential therapeutics for Parkinson\u2019s and Alzheimer\u2019s diseases: a review. Mol Neurobiol 57:4878\u20134890","journal-title":"Mol Neurobiol"},{"key":"1259_CR43","doi-asserted-by":"crossref","first-page":"A009431","DOI":"10.1101\/cshperspect.a009431","volume":"2","author":"PG Coune","year":"2012","unstructured":"Coune PG, Schneider BL, Aebischer P (2012) Parkinson\u2019s disease: gene therapies. Cold Spring Harb Perspect Med 2:A009431","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1259_CR44","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/1747493020972240","volume":"16","author":"S Crilly","year":"2021","unstructured":"Crilly S, Withers SE, Allan SM, Parry-Jones AR, Kasher PR (2021) Revisiting promising preclinical intracerebral hemorrhage studies to highlight repurposable drugs for translation. Int J Stroke 16:123\u2013136","journal-title":"Int J Stroke"},{"key":"1259_CR45","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.pbb.2013.10.018","volume":"123","author":"RC Crist","year":"2014","unstructured":"Crist RC, Berrettini WH (2014) Pharmacogenetics of Oprm1. Pharmacol Biochem Behav 123:25\u201333","journal-title":"Pharmacol Biochem Behav"},{"key":"1259_CR46","first-page":"414","volume":"16","author":"MG Crowley","year":"2017","unstructured":"Crowley MG, Grant Liska M, Lippert T, Corey S, Borlongan CV (2017) Utilizing delta opioid receptors and peptides for cytoprotection: implications in stroke and other neurological disorders. CNS Neurol Disord Drug Targets (Former Curr Drug Targets CNS Neurol Disord 16:414\u2013424","journal-title":"CNS Neurol Disord Drug Targets (Former Curr Drug Targets CNS Neurol Disord"},{"key":"1259_CR47","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/hipo.20891","volume":"22","author":"M Cuellar-Herrera","year":"2012","unstructured":"Cuellar-Herrera M, Velasco AL, Velasco F, Chavez L, Orozco-Suarez S, Armagan G, Turunc E, Bojnik E, Yalcin A, Benyhe S (2012) Mu opioid receptor MRNA expression, binding, and functional coupling to G-proteins in human epileptic hippocampus. Hippocampus 22:122\u2013127","journal-title":"Hippocampus"},{"key":"1259_CR48","doi-asserted-by":"crossref","first-page":"16227","DOI":"10.1523\/JNEUROSCI.3915-11.2011","volume":"31","author":"J Cui","year":"2011","unstructured":"Cui J, Wang Y, Dong Q, Wu S, Xiao X, Hu J, Chai Z, Zhang Y (2011) Morphine protects against intracellular amyloid toxicity by inducing estradiol release and upregulation of Hsp70. J Neurosci 31:16227\u201316240","journal-title":"J Neurosci"},{"key":"1259_CR49","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","volume":"5","author":"LM De Lau","year":"2006","unstructured":"De Lau LM, Breteler MM (2006) Epidemiology of Parkinson\u2019s disease. Lancet Neurol 5:525\u2013535","journal-title":"Lancet Neurol"},{"key":"1259_CR50","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ceca.2009.03.003","volume":"45","author":"L De Petrocellis","year":"2009","unstructured":"De Petrocellis L, Di Marzo V (2009) Role of endocannabinoids and endovanilloids In Ca2+ signalling. Cell Calcium 45:611\u2013624","journal-title":"Cell Calcium"},{"key":"1259_CR51","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1136\/jnnp.62.1.10","volume":"62","author":"MD De Rijk","year":"1997","unstructured":"De Rijk MD, Tzourio C, Breteler M, Dartigues J, Amaducci L, L\u00f3pez-Pousa S, Manubens-Bertran J, Alperovitch A, Rocca WA (1997) Prevalence of Parkinsonism and Parkinson\u2019s disease in Europe: the Europarkinson Collaborative Study. European Community Concerted Action on the epidemiology of Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 62:10\u201315","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1259_CR52","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1474-4422(15)00006-X","volume":"14","author":"B Dehay","year":"2015","unstructured":"Dehay B, Bourdenx M, Gorry P, Przedborski S, Vila M, Hunot S, Singleton A, Olanow CW, Merchant KM, Bezard E (2015) Targeting \u03b1-synuclein for treatment of Parkinson\u2019s disease: mechanistic and therapeutic considerations. Lancet Neurol 14:855\u2013866","journal-title":"Lancet Neurol"},{"key":"1259_CR53","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0166-2236(90)90110-V","volume":"13","author":"MR Delong","year":"1990","unstructured":"Delong MR (1990) Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13:281\u2013285","journal-title":"Trends Neurosci"},{"key":"1259_CR54","doi-asserted-by":"crossref","first-page":"31691","DOI":"10.1074\/jbc.M112.354522","volume":"287","author":"P Desplats","year":"2012","unstructured":"Desplats P, Spencer B, Crews L, Pathel P, Morvinski-Friedmann D, Kosberg K, Roberts S, Patrick C, Winner B, Winkler J (2012) \u03b1-Synuclein induces alterations in adult neurogenesis in Parkinson disease models via P53-mediated repression of Notch1. J Biol Chem 287:31691\u201331702","journal-title":"J Biol Chem"},{"key":"1259_CR55","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nrd.2018.110","volume":"17","author":"BE Deverman","year":"2018","unstructured":"Deverman BE, Ravina BM, Bankiewicz KS, Paul SM, Sah DW (2018) Gene therapy for neurological disorders: progress and prospects. Nat Rev Drug Discov 17:641\u2013659","journal-title":"Nat Rev Drug Discov"},{"key":"1259_CR56","doi-asserted-by":"crossref","first-page":"E493","DOI":"10.1016\/S1470-2045(14)70263-3","volume":"15","author":"CI Diakos","year":"2014","unstructured":"Diakos CI, Charles KA, Mcmillan DC, Clarke SJ (2014) Cancer-related inflammation and treatment effectiveness. Lancet Oncol 15:E493\u2013E503","journal-title":"Lancet Oncol"},{"key":"1259_CR57","first-page":"1","volume-title":"Impact of Nlrp3 inflammasome inhibition on a model of A\u03b2-induced toxicity","author":"DAM Dias","year":"2021","unstructured":"Dias DAM (2021) Impact of Nlrp3 inflammasome inhibition on a model of A\u03b2-induced toxicity. Universidade de Lisboa, Faculdade de Medicina de Lisboa, pp 1\u201385"},{"key":"1259_CR58","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/bja\/aer115","volume":"107","author":"N Dietis","year":"2011","unstructured":"Dietis N, Rowbotham D, Lambert D (2011) Opioid receptor subtypes: fact or artifact? Br J Anaesth 107:8\u201318","journal-title":"Br J Anaesth"},{"key":"1259_CR59","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1152\/jn.00938.2000","volume":"87","author":"VH Do","year":"2002","unstructured":"Do VH, Martinez CO, Martinez JL Jr, Derrick BE (2002) Long-term potentiation in direct perforant path projections to the hippocampal Ca3 region in vivo. J Neurophysiol 87:669\u2013678","journal-title":"J Neurophysiol"},{"key":"1259_CR60","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ejphar.2015.07.018","volume":"763","author":"S Dogra","year":"2015","unstructured":"Dogra S, Yadav PN (2015) Biased agonism at kappa opioid receptors: implication in pain and mood disorders. Eur J Pharmacol 763:184\u2013190","journal-title":"Eur J Pharmacol"},{"key":"1259_CR61","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0278-5846(01)00161-0","volume":"25","author":"G Drolet","year":"2001","unstructured":"Drolet G, Dumont \u00c9C, Gosselin I, Kinkead R, Laforest S, Trottier J-F (2001) Role of endogenous opioid system in the regulation of the stress response. Prog Neuro-Psychopharmacol Biol Psychiatry 25:729\u2013741","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"1259_CR62","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0091-3057(84)90224-7","volume":"21","author":"J Dum","year":"1984","unstructured":"Dum J, Herz A (1984) Endorphinergic modulation of neural reward systems indicated by behavioural changes. Pharmacol Biochem Behav 21:259\u2013266","journal-title":"Pharmacol Biochem Behav"},{"key":"1259_CR63","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1212\/01.CPJ.0000436213.11132.8e","volume":"3","author":"MC Eldaief","year":"2013","unstructured":"Eldaief MC, Press DZ, Pascual-Leone A (2013) Transcranial magnetic stimulation in neurology: a review of established and prospective applications. Neurol Clin Pract 3:519\u2013526","journal-title":"Neurol Clin Pract"},{"key":"1259_CR64","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0006-8993(80)90237-1","volume":"199","author":"P Emson","year":"1980","unstructured":"Emson P, Arregui A, Clement-Jones V, Sandberg BEB, Rossor M (1980) Regional distribution of methionine-enkephalin and substance P-like immunoreactivity in normal human brain and in Huntington\u2019s disease. Brain Res 199:147\u2013160","journal-title":"Brain Res"},{"key":"1259_CR65","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1111\/bph.12492","volume":"171","author":"S Fagan","year":"2014","unstructured":"Fagan S, Campbell V (2014) The influence of cannabinoids on generic traits of neurodegeneration. Br J Pharmacol 171:1347\u20131360","journal-title":"Br J Pharmacol"},{"key":"1259_CR66","doi-asserted-by":"crossref","first-page":"230","DOI":"10.2174\/138945012799201612","volume":"13","author":"Y Feng","year":"2012","unstructured":"Feng Y, He X, Yang Y, Chao D, Lazarus LH, Xia Y (2012) Current research on opioid receptor function. Curr Drug Targets 13:230\u2013246","journal-title":"Curr Drug Targets"},{"key":"1259_CR67","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3389\/fncel.2018.00441","volume":"12","author":"FF Ferreira","year":"2018","unstructured":"Ferreira FF, Ribeiro FF, Rodrigues RS, Sebasti\u00e3o AM, Xapelli S (2018) Brain-derived neurotrophic factor (Bdnf) role in cannabinoid-mediated neurogenesis. Front Cell Neurosci 12:441","journal-title":"Front Cell Neurosci"},{"key":"1259_CR68","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.nurt.2008.05.002","volume":"5","author":"A Fisher","year":"2008","unstructured":"Fisher A (2008) Cholinergic treatments with emphasis on M1 muscarinic agonists as potential disease-modifying agents for Alzheimer\u2019s disease. Neurotherapeutics 5:433\u2013442","journal-title":"Neurotherapeutics"},{"key":"1259_CR69","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.prostaglandins.2013.02.002","volume":"102","author":"B Fonseca","year":"2013","unstructured":"Fonseca B, Costa M, Almada M, Correia-Da-Silva G, Teixeira N (2013) Endogenous cannabinoids revisited: a biochemistry perspective. Prostaglandins Other Lipid Mediat 102:13\u201330","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"1259_CR70","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.neubiorev.2006.11.005","volume":"32","author":"JT Gale","year":"2008","unstructured":"Gale JT, Amirnovin R, Williams ZM, Flaherty AW, Eskandar EN (2008) From symphony to cacophony: pathophysiology of the human basal ganglia in Parkinson disease. Neurosci Biobehav Rev 32:378\u2013387","journal-title":"Neurosci Biobehav Rev"},{"key":"1259_CR71","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.neuroscience.2011.11.060","volume":"202","author":"C-J Gao","year":"2012","unstructured":"Gao C-J, Niu L, Ren P-C, Wang W, Zhu C, Li Y-Q, Chai W, Sun X-D (2012) Hypoxic preconditioning attenuates global cerebral ischemic injury following asphyxial cardiac arrest through regulation of delta opioid receptor system. Neuroscience 202:352\u2013362","journal-title":"Neuroscience"},{"key":"1259_CR72","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1042\/BST20130198","volume":"41","author":"D Garc\u00eda-Ovejero","year":"2013","unstructured":"Garc\u00eda-Ovejero D, Ar\u00e9valo-Mart\u00edn \u00c1, Navarro-Galve B, Pinteaux E, Molina-Holgado E, Molina-Holgado F (2013) Neuroimmmune interactions of cannabinoids in neurogenesis: focus on interleukin-1\u03b2 (Il-1\u03b2) signalling. Biochem Soc Trans 41:1577\u20131582","journal-title":"Biochem Soc Trans"},{"key":"1259_CR73","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/bph.12139","volume":"169","author":"N Garrido-Mesa","year":"2013","unstructured":"Garrido-Mesa N, Zarzuelo A, G\u00e1lvez J (2013) Minocycline: far beyond an antibiotic. Br J Pharmacol 169:337\u2013352","journal-title":"Br J Pharmacol"},{"key":"1259_CR74","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.euroneuro.2003.08.003","volume":"13","author":"MA Gerrits","year":"2003","unstructured":"Gerrits MA, Lesscher HB, Van Ree JM (2003) Drug dependence and the endogenous opioid system. Eur Neuropsychopharmacol 13:424\u2013434","journal-title":"Eur Neuropsychopharmacol"},{"key":"1259_CR75","doi-asserted-by":"crossref","first-page":"8920","DOI":"10.3390\/ijms22168920","volume":"22","author":"C Giuliano","year":"2021","unstructured":"Giuliano C, Francavilla M, Ongari G, Petese A, Ghezzi C, Rossini N, Blandini F, Cerri S (2021) Neuroprotective and symptomatic effects of cannabidiol in an animal model of Parkinson\u2019s disease. Int J Mol Sci 22:8920","journal-title":"Int J Mol Sci"},{"key":"1259_CR76","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.mcn.2008.05.001","volume":"38","author":"MB Goncalves","year":"2008","unstructured":"Goncalves MB, Suetterlin P, Yip P, Molina-Holgado F, Walker DJ, Oudin MJ, Zentar MP, Pollard S, Y\u00e1\u00f1ez-Mu\u00f1oz RJ, Williams G (2008) A diacylglycerol lipase-Cb2 cannabinoid pathway regulates adult subventricular zone neurogenesis in an age-dependent manner. Mol Cell Neurosci 38:526\u2013536","journal-title":"Mol Cell Neurosci"},{"key":"1259_CR77","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3390\/life12010063","volume":"12","author":"J Grigoletto","year":"2022","unstructured":"Grigoletto J, Schechter M, Sharon R (2022) Loss of corticostriatal mu-opioid receptors in \u03b1-synuclein transgenic mouse brains. Life 12:63","journal-title":"Life"},{"key":"1259_CR78","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1111\/bph.13809","volume":"175","author":"T G\u00fcnther","year":"2018","unstructured":"G\u00fcnther T, Dasgupta P, Mann A, Miess E, Kliewer A, Fritzwanker S, Steinborn R, Schulz S (2018) Targeting multiple opioid receptors-improved analgesics with reduced side effects? Br J Pharmacol 175:2857\u20132868","journal-title":"Br J Pharmacol"},{"key":"1259_CR79","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/brain\/awm012","volume":"130","author":"A Hammers","year":"2007","unstructured":"Hammers A, Asselin M-C, Hinz R, Kitchen I, Brooks DJ, Duncan JS, Koepp MJ (2007) Upregulation of opioid receptor binding following spontaneous epileptic seizures. Brain 130:1009\u20131016","journal-title":"Brain"},{"key":"1259_CR80","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/mds.27874","volume":"35","author":"ME Haque","year":"2020","unstructured":"Haque ME, Akther M, Jakaria M, Kim IS, Azam S, Choi DK (2020) Targeting the microglial NLRP3 inflammasome and its role in Parkinson\u2019s disease. Mov Disord 35:20\u201333","journal-title":"Mov Disord"},{"key":"1259_CR81","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41392-021-00569-5","volume":"6","author":"AT He","year":"2021","unstructured":"He AT, Liu J, Li F, Yang BB (2021) Targeting circular RNAS as a therapeutic approach: current strategies and challenges. Signal Transduct Target Ther 6:185","journal-title":"Signal Transduct Target Ther"},{"key":"1259_CR82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-022-02496-w","volume":"19","author":"A Heidari","year":"2022","unstructured":"Heidari A, Yazdanpanah N, Rezaei N (2022) The role of Toll-like receptors and neuroinflammation in Parkinson\u2019s disease. J Neuroinflammation 19:1\u201321","journal-title":"J Neuroinflammation"},{"key":"1259_CR83","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1006\/exnr.2001.7727","volume":"171","author":"B Henry","year":"2001","unstructured":"Henry B, Fox SH, Crossman AR, Brotchie JM (2001) \u03bc-and \u03b4-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson\u2019s disease. Exp Neurol 171:139\u2013146","journal-title":"Exp Neurol"},{"key":"1259_CR84","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s002130050169","volume":"129","author":"A Herz","year":"1997","unstructured":"Herz A (1997) Endogenous opioid systems and alcohol addiction. Psychopharmacology 129:99\u2013111","journal-title":"Psychopharmacology"},{"key":"1259_CR86","first-page":"261","volume":"13","author":"M Hill","year":"2000","unstructured":"Hill M, Hille C, Brotchie J (2000) D-opioid receptor agonists as a therapeutic approach in Parkinson\u2019s disease. Drug News Perspect 13:261\u2013268","journal-title":"Drug News Perspect"},{"key":"1259_CR87","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0014-5793(99)01253-3","volume":"459","author":"CJ Hillard","year":"1999","unstructured":"Hillard CJ, Muthian S, Kearn CS (1999) Effects of Cb1 cannabinoid receptor activation on cerebellar granule cell nitric oxide synthase activity. FEBS Lett 459:277\u2013281","journal-title":"FEBS Lett"},{"key":"1259_CR88","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1474-4422(09)70062-6","volume":"8","author":"EC Hirsch","year":"2009","unstructured":"Hirsch EC, Hunot S (2009) Neuroinflammation in Parkinson\u2019s disease: a target for neuroprotection? Lancet Neurol 8:382\u2013397","journal-title":"Lancet Neurol"},{"key":"1259_CR89","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.parkreldis.2019.07.018","volume":"66","author":"FL Hitti","year":"2019","unstructured":"Hitti FL, Yang AI, Gonzalez-Alegre P, Baltuch GH (2019) Human gene therapy approaches for the treatment of Parkinson\u2019s disease: an overview of current and completed clinical trials. Parkinsonism Relat Disord 66:16\u201324","journal-title":"Parkinsonism Relat Disord"},{"key":"1259_CR90","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1152\/jn.2001.85.3.1153","volume":"85","author":"GO Hjelmstad","year":"2001","unstructured":"Hjelmstad GO, Fields HL (2001) Kappa opioid receptor inhibition of glutamatergic transmission in the nucleus accumbens shell. J Neurophysiol 85:1153\u20131158","journal-title":"J Neurophysiol"},{"key":"1259_CR91","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/ajmg.b.32429","volume":"174","author":"E Horgusluoglu","year":"2017","unstructured":"Horgusluoglu E, Nudelman K, Nho K, Saykin AJ (2017) Adult neurogenesis and neurodegenerative diseases: a systems biology perspective. Am J Med Genet B Neuropsychiatr Genet 174:93\u2013112","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"1259_CR92","first-page":"787","volume":"73","author":"O Hornyewicz","year":"1961","unstructured":"Hornyewicz O, Birkmayer W, Der L (1961) 3, 4 dioxyphennyl alanin (L-Dopa): Effekt bei der Parkinson-Akineses. Wien Klin Wschr 73:787","journal-title":"Wien Klin Wschr"},{"key":"1259_CR93","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/cns.13045","volume":"24","author":"JZ Huang","year":"2018","unstructured":"Huang JZ, Ren Y, Xu Y, Chen T, Xia TC, Li ZR, Zhao JN, Hua F, Sheng SY, Xia Y (2018) The delta-opioid receptor and Parkinson\u2019s disease. CNS Neurosci Ther 24:1089\u20131099","journal-title":"CNS Neurosci Ther"},{"key":"1259_CR94","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.plipres.2016.02.002","volume":"62","author":"FA Iannotti","year":"2016","unstructured":"Iannotti FA, Di Marzo V, Petrosino S (2016) Endocannabinoids and endocannabinoid-related mediators: targets, metabolism and role in neurological disorders. Prog Lipid Res 62:107\u2013128","journal-title":"Prog Lipid Res"},{"key":"1259_CR95","doi-asserted-by":"crossref","first-page":"2ra4","DOI":"10.1126\/scitranslmed.3000130","volume":"1","author":"B Jarraya","year":"2009","unstructured":"Jarraya B, Boulet S, Scott Ralph G, Jan C, Bonvento G, Azzouz M, Miskin JE, Shin M, Delzescaux T, Drouot X (2009) Dopamine gene therapy for Parkinson\u2019s disease in a nonhuman primate without associated dyskinesia. Sci Transl Med 1:2ra4","journal-title":"Sci Transl Med"},{"key":"1259_CR96","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1172\/JCI25509","volume":"115","author":"W Jiang","year":"2005","unstructured":"Jiang W, Zhang Y, Xiao L, Van Cleemput J, Ji S-P, Bai G, Zhang X (2005) Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic-and antidepressant-like effects. J Clin Investig 115:3104\u20133116","journal-title":"J Clin Investig"},{"key":"1259_CR97","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1084\/jem.20171419","volume":"214","author":"H Jiang","year":"2017","unstructured":"Jiang H, He H, Chen Y, Huang W, Cheng J, Ye J, Wang A, Tao J, Wang C, Liu Q (2017) Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J Exp Med 214:3219\u20133238","journal-title":"J Exp Med"},{"key":"1259_CR98","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/mds.25273","volume":"28","author":"LV Kalia","year":"2013","unstructured":"Kalia LV, Brotchie JM, Fox SH (2013) Novel nondopaminergic targets for motor features of Parkinson\u2019s disease: review of recent trials. Mov Disord 28:131\u2013144","journal-title":"Mov Disord"},{"key":"1259_CR99","doi-asserted-by":"crossref","first-page":"118165","DOI":"10.1016\/j.lfs.2020.118165","volume":"259","author":"A Karimian","year":"2020","unstructured":"Karimian A, Gorjizadeh N, Alemi F, Asemi Z, Azizian K, Soleimanpour J, Malakouti F, Targhazeh N, Majidinia M, Yousefi B (2020) Crispr\/Cas9 novel therapeutic road for the treatment of neurodegenerative diseases. Life Sci 259:118165","journal-title":"Life Sci"},{"key":"1259_CR100","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1124\/jpet.106.107698","volume":"319","author":"SH Kim","year":"2006","unstructured":"Kim SH, Won SJ, Mao XO, Ledent C, Jin K, Greenberg DA (2006) Role for neuronal nitric-oxide synthase in cannabinoid-induced neurogenesis. J Pharmacol Exp Ther 319:150\u2013154","journal-title":"J Pharmacol Exp Ther"},{"key":"1259_CR101","doi-asserted-by":"crossref","first-page":"101618","DOI":"10.1016\/j.arr.2022.101618","volume":"78","author":"EC Kip","year":"2022","unstructured":"Kip EC, Parr-Brownlie LC (2022) Reducing neuroinflammation via therapeutic compounds and lifestyle to prevent or delay progression of Parkinson\u2019s disease. Prevention of neuroinflammation in Parkinson\u2019s disease. Ageing Res Rev 78:101618","journal-title":"Ageing Res Rev"},{"key":"1259_CR102","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10571-018-0632-3","volume":"39","author":"MO Klein","year":"2019","unstructured":"Klein MO, Battagello DS, Cardoso AR, Hauser DN, Bittencourt JC, Correa RG (2019) Dopamine: functions, signalling, and association with neurological diseases. Cell Mol Neurobiol 39:31\u201359","journal-title":"Cell Mol Neurobiol"},{"key":"1259_CR103","first-page":"1","volume":"6","author":"S Klein","year":"2020","unstructured":"Klein S (2020) Alpha-synuclein promotes dopaminergic neuron death in Parkinson\u2019s disease through microglial and NLRP3 activation. USURJ Univ Sask Undergr Res J 6:1\u201311","journal-title":"USURJ Univ Sask Undergr Res J"},{"key":"1259_CR104","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/mds.25344","volume":"28","author":"JH Kordower","year":"2013","unstructured":"Kordower JH, Bjorklund A (2013) Trophic factor gene therapy for Parkinson\u2019s disease. Mov Disord 28:96\u2013109","journal-title":"Mov Disord"},{"key":"1259_CR105","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.3390\/ijms22031324","volume":"22","author":"JH Lee","year":"2021","unstructured":"Lee JH, Kim HJ, Kim JU, Yook TH, Kim KH, Lee JY, Yang G (2021) A novel treatment strategy by natural products in NLRP3 inflammasome-mediated neuroinflammation in Alzheimer\u2019s and Parkinson\u2019s disease. Int J Mol Sci 22:1324","journal-title":"Int J Mol Sci"},{"key":"1259_CR106","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.peptides.2004.02.006","volume":"25","author":"SF Leibowitz","year":"2004","unstructured":"Leibowitz SF, Wortley KE (2004) Hypothalamic control of energy balance: different peptides, different functions. Peptides 25:473\u2013504","journal-title":"Peptides"},{"key":"1259_CR107","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0278-5846(03)00019-8","volume":"27","author":"N Lev","year":"2003","unstructured":"Lev N, Melamed E, Offen D (2003) Apoptosis and Parkinson\u2019s disease. Prog Neuro Psychopharmacol Biol Psychiatry 27:245\u2013250","journal-title":"Prog Neuro Psychopharmacol Biol Psychiatry"},{"key":"1259_CR108","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1474-4422(11)70039-4","volume":"10","author":"PA Lewitt","year":"2011","unstructured":"Lewitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, Kostyk SK, Thomas K, Sarkar A, Siddiqui MS (2011) Aav2-Gad gene therapy for advanced Parkinson\u2019s disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 10:309\u2013319","journal-title":"Lancet Neurol"},{"key":"1259_CR109","doi-asserted-by":"crossref","first-page":"582","DOI":"10.2174\/138955711795906905","volume":"11","author":"JP Little","year":"2011","unstructured":"Little JP, Villanueva EB, Klegeris A (2011) Therapeutic potential of cannabinoids in the treatment of neuroinflammation associated with Parkinson\u2019s disease. Mini Rev Med Chem 11:582\u2013590","journal-title":"Mini Rev Med Chem"},{"key":"1259_CR110","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/j.1471-4159.1984.tb12812.x","volume":"43","author":"C Llorens-Cortes","year":"1984","unstructured":"Llorens-Cortes C, Javoy-Agid F, Agid Y, Taquet H, Schwartz J (1984) Enkephalinergic markers in substantia nigra and caudate nucleus from Parkinsonian subjects. J Neurochem 43:874\u2013877","journal-title":"J Neurochem"},{"key":"1259_CR111","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/brain\/awl384","volume":"130","author":"S Loacker","year":"2007","unstructured":"Loacker S, Sayyah M, Wittmann W, Herzog H, Schwarzer C (2007) Endogenous dynorphin in epileptogenesis and epilepsy: anticonvulsant net effect via kappa opioid receptors. Brain 130:1017\u20131028","journal-title":"Brain"},{"key":"1259_CR112","doi-asserted-by":"crossref","first-page":"9472","DOI":"10.3390\/ijms22179472","volume":"22","author":"H Lowe","year":"2021","unstructured":"Lowe H, Toyang N, Steele B, Bryant J, Ngwa W (2021) The endocannabinoid system: a potential target for the treatment of various diseases. Int J Mol Sci 22:9472","journal-title":"Int J Mol Sci"},{"key":"1259_CR114","first-page":"1","volume":"51","author":"M Lu","year":"2015","unstructured":"Lu M, Ueno S (2015) Deep transcranial magnetic stimulation using figure-of-eight and halo coils. IEEE Trans Magn 51:1\u20134","journal-title":"IEEE Trans Magn"},{"key":"1259_CR113","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.biopsych.2015.07.028","volume":"79","author":"H-C Lu","year":"2016","unstructured":"Lu H-C, Mackie K (2016) An introduction to the endogenous cannabinoid system. Biol Psychiatry 79:516\u2013525","journal-title":"Biol Psychiatry"},{"key":"1259_CR115","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1124\/jpet.107.120279","volume":"322","author":"MM Lunzer","year":"2007","unstructured":"Lunzer MM, Portoghese PS (2007) Selectivity of \u03b4-and \u03ba-opioid ligands depends on the route of central administration in mice. J Pharmacol Exp Ther 322:166\u2013171","journal-title":"J Pharmacol Exp Ther"},{"key":"1259_CR116","doi-asserted-by":"crossref","first-page":"117906951879363","DOI":"10.1177\/1179069518793639","volume":"12","author":"DI Lurie","year":"2018","unstructured":"Lurie DI (2018) An integrative approach to neuroinflammation in psychiatric disorders and neuropathic pain. J Exp Neurosci 12:1179069518793639","journal-title":"J Exp Neurosci"},{"key":"1259_CR117","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.neulet.2009.10.011","volume":"467","author":"P Maison","year":"2009","unstructured":"Maison P, Walker DJ, Walsh FS, Williams G, Doherty P (2009) Bdnf regulates neuronal sensitivity to endocannabinoids. Neurosci Lett 467:90\u201394","journal-title":"Neurosci Lett"},{"key":"1259_CR118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40035-017-0099-z","volume":"6","author":"P Maiti","year":"2017","unstructured":"Maiti P, Manna J, Dunbar GL (2017) Current understanding of the molecular mechanisms in Parkinson\u2019s disease: targets for potential treatments. Transl Neurodegener 6:1\u201335","journal-title":"Transl Neurodegener"},{"key":"1259_CR119","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/mds.26561","volume":"31","author":"R Manenti","year":"2016","unstructured":"Manenti R, Brambilla M, Benussi A, Rosini S, Cobelli C, Ferrari C, Petesi M, Orizio I, Padovani A, Borroni B (2016) Mild cognitive impairment in Parkinson\u2019s disease is improved by transcranial direct current stimulation combined with physical therapy. Mov Disord 31:715\u2013724","journal-title":"Mov Disord"},{"key":"1259_CR120","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/0166-2236(88)90093-8","volume":"11","author":"A Mansour","year":"1988","unstructured":"Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ (1988) Anatomy of CNS opioid receptors. Trends Neurosci 11:308\u2013314","journal-title":"Trends Neurosci"},{"key":"1259_CR121","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.tips.2005.08.007","volume":"26","author":"B Marchetti","year":"2005","unstructured":"Marchetti B, Abbracchio MP (2005) To be or not to be (inflamed)\u2014is that the question in anti-inflammatory drug therapy of neurodegenerative disorders? Trends Pharmacol Sci 26:517\u2013525","journal-title":"Trends Pharmacol Sci"},{"key":"1259_CR122","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00018-012-1062-x","volume":"70","author":"F Marxreiter","year":"2013","unstructured":"Marxreiter F, Regensburger M, Winkler J (2013) Adult neurogenesis in Parkinson\u2019s disease. Cell Mol Life Sci 70:459\u2013473","journal-title":"Cell Mol Life Sci"},{"key":"1259_CR123","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3389\/fnsys.2015.00027","volume":"9","author":"R Mckendrick","year":"2015","unstructured":"Mckendrick R, Parasuraman R, Ayaz H (2015) Wearable functional near infrared spectroscopy (fNIRS) and transcranial direct current stimulation (tDCS): expanding vistas for neurocognitive augmentation. Front Syst Neurosci 9:27","journal-title":"Front Syst Neurosci"},{"key":"1259_CR124","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/ana.20186","volume":"56","author":"KSP Mcnaught","year":"2004","unstructured":"Mcnaught KSP, Perl DP, Brownell AL, Olanow CW (2004) Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson\u2019s disease. Ann Neurol 56:149\u2013162","journal-title":"Ann Neurol"},{"key":"1259_CR125","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/bph.14893","volume":"177","author":"D Mercatelli","year":"2020","unstructured":"Mercatelli D, Bezard E, Eleopra R, Zaveri NT, Morari M (2020) Managing Parkinson\u2019s disease: moving ON with NOP. Br J Pharmacol 177:28\u201347","journal-title":"Br J Pharmacol"},{"key":"1259_CR126","first-page":"213","volume-title":"NOP receptor ligands and Parkinson\u2019s disease","author":"D Mercatelli","year":"2019","unstructured":"Mercatelli D, Pisan\u00f2 CA, Novello S, Morari M (2019) NOP receptor ligands and Parkinson\u2019s disease. The Nociceptin\/Orphanin FQ Peptide Receptor, pp 213\u2013232"},{"key":"1259_CR127","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.phrs.2007.09.008","volume":"56","author":"V Micale","year":"2007","unstructured":"Micale V, Mazzola C, Drago F (2007) Endocannabinoids and neurodegenerative diseases. Pharmacol Res 56:382\u2013392","journal-title":"Pharmacol Res"},{"key":"1259_CR128","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.npep.2011.03.002","volume":"45","author":"J Mika","year":"2011","unstructured":"Mika J, Obara I, Przewlocka B (2011) The role of nociceptin and dynorphin in chronic pain: implications of neuro-glial interaction. Neuropeptides 45:247\u2013261","journal-title":"Neuropeptides"},{"key":"1259_CR129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1326-10-1","volume":"10","author":"SV More","year":"2015","unstructured":"More SV, Choi D-K (2015) Promising cannabinoid-based therapies for Parkinson\u2019s disease: motor symptoms to neuroprotection. Mol Neurodegener 10:1\u201326","journal-title":"Mol Neurodegener"},{"key":"1259_CR130","first-page":"59","volume-title":"Cannabinoids in health and disease","author":"T Morera-Herreras","year":"2016","unstructured":"Morera-Herreras T, Miguelez C, Aristieta A, Torrecilla M, Ruiz-Ortega JA, Ugedo L (2016) Cannabinoids and motor control of the basal ganglia: therapeutic potential in movement disorders. In: Meccariello R, Chianese R (eds) Cannabinoids in health and disease, pp 59\u201392"},{"key":"1259_CR131","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.neuropharm.2018.02.023","volume":"135","author":"J Motyl","year":"2018","unstructured":"Motyl J, Przykaza \u0141, Boguszewski PM, Kosson P, Strosznajder JB (2018) Pramipexole and Fingolimod exert neuroprotection in a mouse model of Parkinson\u2019s disease by activation of sphingosine kinase 1 and Akt kinase. Neuropharmacology 135:139\u2013150","journal-title":"Neuropharmacology"},{"key":"1259_CR132","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/BF00432213","volume":"86","author":"RF Mucha","year":"1985","unstructured":"Mucha RF, Herz A (1985) Motivational properties of Kappa and Mu opioid receptor agonists studied with place and taste preference conditioning. Psychopharmacology 86:274\u2013280","journal-title":"Psychopharmacology"},{"key":"1259_CR133","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1111\/bph.12411","volume":"171","author":"N Murataeva","year":"2014","unstructured":"Murataeva N, Straiker A, Mackie K (2014) Parsing the players: 2-arachidonoylglycerol synthesis and degradation in the CNS. Br J Pharmacol 171:1379\u20131391","journal-title":"Br J Pharmacol"},{"key":"1259_CR134","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchromb.2016.06.002","volume":"1028","author":"C Mwanza","year":"2016","unstructured":"Mwanza C, Chen Z, Zhang Q, Chen S, Wang W, Deng H (2016) Simultaneous HPLC-APCI-MS\/MS quantification of endogenous cannabinoids and glucocorticoids in hair. J Chromatogr B 1028:1\u201310","journal-title":"J Chromatogr B"},{"key":"1259_CR135","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.3233\/JPD-223290","volume":"12","author":"LTN Nguyen","year":"2022","unstructured":"Nguyen LTN, Nguyen HD, Kim YJ, Nguyen TT, Lai TT, Lee YK, Ma H-I, Kim YE (2022) Role of NLRP3 inflammasome in Parkinson\u2019s disease and therapeutic considerations. J Parkinson\u2019s Dis 12:2117\u20132133","journal-title":"J Parkinson's Dis"},{"key":"1259_CR136","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.neuroscience.2005.06.025","volume":"135","author":"MM Nieto","year":"2005","unstructured":"Nieto MM, Guen S, Kieffer B, Roques B, Noble F (2005) Physiological control of emotion-related behaviours by endogenous enkephalins involves essentially the delta opioid receptors. Neuroscience 135:305\u2013313","journal-title":"Neuroscience"},{"key":"1259_CR137","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.conb.2014.03.017","volume":"29","author":"T Ohno-Shosaku","year":"2014","unstructured":"Ohno-Shosaku T, Kano M (2014) Endocannabinoid-mediated retrograde modulation of synaptic transmission. Curr Opin Neurobiol 29:1\u20138","journal-title":"Curr Opin Neurobiol"},{"key":"1259_CR138","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMct1208070","volume":"367","author":"MS Okun","year":"2012","unstructured":"Okun MS (2012) Deep-brain stimulation for Parkinson\u2019s disease. N Engl J Med 367:1529\u20131538","journal-title":"N Engl J Med"},{"key":"1259_CR139","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/mds.21813","volume":"23","author":"SS O'sullivan","year":"2008","unstructured":"O\u2019sullivan SS, Williams DR, Gallagher DA, Massey LA, Silveira-Moriyama L, Lees AJ (2008) Nonmotor symptoms as presenting complaints in Parkinson\u2019s disease: a clinicopathological study. Mov Disord 23:101\u2013106","journal-title":"Mov Disord"},{"key":"1259_CR140","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1096\/fj.06-6164fje","volume":"20","author":"J Palazuelos","year":"2006","unstructured":"Palazuelos J, Aguado T, Egia A, Mechoulam R, Guzm\u00e1n M, Galve-Roperh I, Palazuelos J, Aguado T, Egia A, Mechoulam R (2006) Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB J 20:2405\u20132407","journal-title":"FASEB J"},{"key":"1259_CR141","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1074\/jbc.M111.291294","volume":"287","author":"J Palazuelos","year":"2012","unstructured":"Palazuelos J, Ortega Z, D\u00edaz-Alonso J, Guzm\u00e1n M, Galve-Roperh I (2012) CB2 Cannabinoid receptors promote neural progenitor cell proliferation via mTORC1 signalling. J Biol Chem 287:1198\u20131209","journal-title":"J Biol Chem"},{"key":"1259_CR142","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1528-1167.2008.01779.x","volume":"50","author":"G Panuccio","year":"2009","unstructured":"Panuccio G, Curia G, Colosimo A, Cruccu G, Avoli M (2009) Epileptiform synchronization in the cingulate cortex. Epilepsia 50:521\u2013536","journal-title":"Epilepsia"},{"key":"1259_CR143","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/ana.410390107","volume":"39","author":"Parkinson Study Group","year":"1996","unstructured":"Parkinson Study Group (1996) Impact of deprenyl and tocopherol treatment on Parkinson\u2019s disease in DATATOP patients requiring levodopa. Ann Neurol 39:37\u201345","journal-title":"Ann Neurol"},{"key":"1259_CR144","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1056\/NEJMoa033447","volume":"351","author":"Parkinson Study Group","year":"2004","unstructured":"Parkinson Study Group (2004) Levodopa and the progression of Parkinson\u2019s disease. N Engl J Med 351:2498\u20132508","journal-title":"N Engl J Med"},{"key":"1259_CR145","first-page":"77","volume":"4","author":"P Patil","year":"2012","unstructured":"Patil P, Chaudhari P, Sahu M, Duragkar N (2012) Review article on gene therapy. Res J Pharmacol Pharmacodyn 4:77\u201383","journal-title":"Res J Pharmacol Pharmacodyn"},{"key":"1259_CR146","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1517\/14728222.2016.1121237","volume":"20","author":"E Pena-Altamira","year":"2016","unstructured":"Pena-Altamira E, Prati F, Massenzio F, Virgili M, Contestabile A, Bolognesi ML, Monti B (2016) Changing paradigm to target microglia in neurodegenerative diseases: from anti-inflammatory strategy to active immunomodulation. Expert Opin Ther Targets 20:627\u2013640","journal-title":"Expert Opin Ther Targets"},{"key":"1259_CR147","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1146\/annurev.ne.06.030183.000445","volume":"6","author":"J Penney","year":"1983","unstructured":"Penney J, Young A (1983) Speculations on the functional anatomy of basal ganglia disorders. Annu Rev Neurosci 6:73\u201394","journal-title":"Annu Rev Neurosci"},{"key":"1259_CR148","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1073\/pnas.84.9.3033","volume":"84","author":"G Perry","year":"1987","unstructured":"Perry G, Friedman R, Shaw G, Chau V (1987) Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proc Natl Acad Sci 84:3033\u20133036","journal-title":"Proc Natl Acad Sci"},{"key":"1259_CR149","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41531-022-00293-z","volume":"8","author":"AF Pike","year":"2022","unstructured":"Pike AF, Szab\u00f2 I, Veerhuis R, Bubacco L (2022) The potential convergence of NLRP3 inflammasome, potassium, and dopamine mechanisms in Parkinson\u2019s disease. NPJ Parkinson\u2019s Dis 8:32","journal-title":"NPJ Parkinson's Dis"},{"key":"1259_CR150","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/bja\/aep179","volume":"103","author":"C Poon","year":"2009","unstructured":"Poon C, Irwin M (2009) Anaesthesia for deep brain stimulation and in patients with implanted neurostimulator devices. Br J Anaesth 103:152\u2013165","journal-title":"Br J Anaesth"},{"key":"1259_CR151","first-page":"20","volume":"19","author":"R Postuma","year":"2012","unstructured":"Postuma R, Romenets SR, Rakheja R (2012) Physician guide non-motor symptoms of Parkinson\u2019s disease. Depression 19:20","journal-title":"Depression"},{"key":"1259_CR152","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.tips.2011.06.008","volume":"32","author":"AA Pradhan","year":"2011","unstructured":"Pradhan AA, Befort K, Nozaki C, Gav\u00e9riaux-Ruff C, Kieffer BL (2011) The delta opioid receptor: an evolving target for the treatment of brain disorders. Trends Pharmacol Sci 32:581\u2013590","journal-title":"Trends Pharmacol Sci"},{"key":"1259_CR153","doi-asserted-by":"crossref","first-page":"PI1","DOI":"10.1016\/0024-3205(93)90615-A","volume":"53","author":"R Przew\u0142ocki","year":"1993","unstructured":"Przew\u0142ocki R, Machelska H, Przew\u0142ocka B (1993) Inhibition of nitric oxide synthase enhances morphine antinociception in the rat spinal cord. Life Sci 53:PI1\u2013PI5","journal-title":"Life Sci"},{"key":"1259_CR154","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s00702-010-0428-1","volume":"117","author":"L Qian","year":"2010","unstructured":"Qian L, Flood PM, Hong J-S (2010) Neuroinflammation is a key player in Parkinson\u2019s disease and a prime target for therapy. J Neural Transm 117:971\u2013979","journal-title":"J Neural Transm"},{"key":"1259_CR155","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/bmj.310.6979.575","volume":"310","author":"N Quinn","year":"1995","unstructured":"Quinn N (1995) Fortnightly review: drug treatment of Parkinson\u2019s disease. BMJ 310:575\u2013579","journal-title":"BMJ"},{"key":"1259_CR156","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.3390\/pharmaceutics14061252","volume":"14","author":"MU Rahman","year":"2022","unstructured":"Rahman MU, Bilal M, Shah JA, Kaushik A, Teissedre P-L, Kujawska M (2022) Crispr-Cas9-based technology and its relevance to gene editing in Parkinson\u2019s disease. Pharmaceutics 14:1252","journal-title":"Pharmaceutics"},{"key":"1259_CR157","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1080\/01480545.2021.1907909","volume":"45","author":"K Raj","year":"2021","unstructured":"Raj K, Gupta G, Singh S (2021) L-theanine ameliorates motor deficit, mitochondrial dysfunction, and neurodegeneration against chronic tramadol induced rats model of Parkinson\u2019s disease. Drug Chem Toxicol 45:2097\u20132108","journal-title":"Drug Chem Toxicol"},{"key":"1259_CR158","doi-asserted-by":"crossref","first-page":"81s","DOI":"10.18433\/J3T886","volume":"11","author":"P Rao","year":"2008","unstructured":"Rao P, Knaus EE (2008) Evolution of nonsteroidal anti-inflammatory drugs (Nsaids): cyclooxygenase (Cox) inhibition and beyond. J Pharm Pharm Sci 11:81s\u2013110s","journal-title":"J Pharm Pharm Sci"},{"key":"1259_CR159","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","volume":"342","author":"O Rascol","year":"2000","unstructured":"Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson\u2019s disease who were treated with ropinirole or levodopa. N Engl J Med 342:1484\u20131491","journal-title":"N Engl J Med"},{"key":"1259_CR160","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008454.pub2","author":"K Rees","year":"2011","unstructured":"Rees K, Stowe R, Patel S, Ives N, Breen K, Clarke CE, Ben-Shlomo Y (2011) Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson\u2019s disease: evidence from observational studies. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD008454.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"1259_CR161","doi-asserted-by":"crossref","first-page":"574","DOI":"10.2174\/187152710793361612","volume":"9","author":"FM Ribeiro","year":"2010","unstructured":"Ribeiro FM, Paquet M, Cregan SP, Ferguson SSG (2010) Group I metabotropic glutamate receptor signalling and its implication in neurological disease. CNS Neurol Disord Drug Targets (Former Curr Drug Targets CNS Neurol Disord) 9:574\u2013595","journal-title":"CNS Neurol Disord Drug Targets (Former Curr Drug Targets CNS Neurol Disord)"},{"key":"1259_CR162","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/BF01243383","volume":"73","author":"J Rinne","year":"1988","unstructured":"Rinne J, S\u00e4k\u00f6 E, Palj\u00e4rvi L, M\u00f6ls\u00e4 P, Rinne U (1988) A comparison of brain choline acetyltransferase activity in Alzheimer\u2019s disease, multi-infarct dementia, and combined dementia. J Neural Transm 73:121\u2013128","journal-title":"J Neural Transm"},{"key":"1259_CR163","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.expneurol.2010.03.030","volume":"224","author":"S Rossi","year":"2010","unstructured":"Rossi S, Bernardi G, Centonze D (2010) The Endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic lateral sclerosis. Exp Neurol 224:92\u2013102","journal-title":"Exp Neurol"},{"key":"1259_CR164","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0196-9781(84)90284-5","volume":"5","author":"SM Sagar","year":"1984","unstructured":"Sagar SM, Beal MF, Marshall PE, Landis DM, Martin JB (1984) Implications of neuropeptides in neurological diseases. Peptides 5:255\u2013262","journal-title":"Peptides"},{"key":"1259_CR165","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.tips.2006.08.002","volume":"27","author":"P Samadi","year":"2006","unstructured":"Samadi P, B\u00e9dard PJ, Rouillard C (2006) Opioids and motor complications in Parkinson\u2019s disease. Trends Pharmacol Sci 27:512\u2013517","journal-title":"Trends Pharmacol Sci"},{"key":"1259_CR166","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/0024-3205(85)90292-9","volume":"37","author":"R Sandyk","year":"1985","unstructured":"Sandyk R (1985) The endogenous opioid system in neurological disorders of the basal ganglia. Life Sci 37:1655\u20131663","journal-title":"Life Sci"},{"key":"1259_CR167","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.tiv.2015.11.004","volume":"30","author":"NAG Santos","year":"2015","unstructured":"Santos NAG, Martins NM, Sisti FM, Fernandes LS, Ferreira RS, Queiroz RHC, Santos AC (2015) The neuroprotection of cannabidiol against MPP+-induced toxicity in PC12 cells involves trkA receptors, upregulation of axonal and synaptic proteins, neuritogenesis, and might be relevant to Parkinson\u2019s disease. Toxicol In Vitro 30:231\u2013240","journal-title":"Toxicol In Vitro"},{"key":"1259_CR168","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.npep.2010.12.004","volume":"45","author":"DS Sauriyal","year":"2011","unstructured":"Sauriyal DS, Jaggi AS, Singh N (2011) Extending pharmacological spectrum of opioids beyond analgesia: multifunctional aspects in different pathophysiological states. Neuropeptides 45:175\u2013188","journal-title":"Neuropeptides"},{"key":"1259_CR169","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nrd2087","volume":"5","author":"AH Schapira","year":"2006","unstructured":"Schapira AH, Bezard E, Brotchie J, Calon F, Collingridge GL, Ferger B, Hengerer B, Hirsch E, Jenner P, Nov\u00e8re NL (2006) Novel pharmacological targets for the treatment of Parkinson\u2019s disease. Nat Rev Drug Discov 5:845\u2013854","journal-title":"Nat Rev Drug Discov"},{"key":"1259_CR170","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.expneurol.2004.11.016","volume":"192","author":"H Scharfman","year":"2005","unstructured":"Scharfman H, Goodman J, Macleod A, Phani S, Antonelli C, Croll S (2005) Increased neurogenesis and the ectopic granule cells after intrahippocampal BDNF infusion in adult rats. Exp Neurol 192:348\u2013356","journal-title":"Exp Neurol"},{"key":"1259_CR171","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1021\/acs.jmedchem.0c01307","volume":"64","author":"AG Schwaid","year":"2020","unstructured":"Schwaid AG, Spencer KB (2020) Strategies for targeting the NLRP3 inflammasome in the clinical and preclinical space. J Med Chem 64:101\u2013122","journal-title":"J Med Chem"},{"key":"1259_CR172","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1159\/000489808","volume":"47","author":"S Sheng","year":"2018","unstructured":"Sheng S, Huang J, Ren Y, Zhi F, Tian X, Wen G, Ding G, Xia TC, Hua F, Xia Y (2018) Neuroprotection against hypoxic\/ischemic injury: \u03b4-opioid receptors and BDNF-TRKB pathway. Cell Physiol Biochem 47:302\u2013315","journal-title":"Cell Physiol Biochem"},{"key":"1259_CR173","doi-asserted-by":"crossref","first-page":"113525","DOI":"10.1016\/j.expneurol.2020.113525","volume":"336","author":"X-L Si","year":"2021","unstructured":"Si X-L, Fang Y-J, Li L-F, Gu L-Y, Yin X-Z, Yan Y-P, Pu J-L, Zhang B-R (2021) From inflammasome to parkinson\u2019s disease: does the NLRP3 inflammasome facilitate exosome secretion and exosomal alpha-synuclein transmission in parkinson\u2019s disease? Exp Neurol 336:113525","journal-title":"Exp Neurol"},{"key":"1259_CR174","doi-asserted-by":"crossref","first-page":"H1953","DOI":"10.1152\/ajpheart.01045.2001","volume":"282","author":"DC Sigg","year":"2002","unstructured":"Sigg DC, Coles JA Jr, Oeltgen PR, Iaizzo PA (2002) Role of \u03b4-opioid receptor agonists on infarct size reduction in swine. Am J Physiol-Heart Circ Physiol 282:H1953\u2013H1960","journal-title":"Am J Physiol-Heart Circ Physiol"},{"key":"1259_CR175","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1134\/S1819712407040034","volume":"1","author":"I Silkis","year":"2007","unstructured":"Silkis I (2007) The role of opioid receptor agonists and antagonists in the treatment of Parkinson\u2019s disease. Neurochem J 1:281\u2013287","journal-title":"Neurochem J"},{"key":"1259_CR176","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nrneurol.2013.56","volume":"9","author":"M Simonato","year":"2013","unstructured":"Simonato M, Bennett J, Boulis NM, Castro MG, Fink DJ, Goins WF, Gray SJ, Lowenstein PR, Vandenberghe LH, Wilson TJ (2013) Progress in gene therapy for neurological disorders. Nat Rev Neurol 9:277\u2013291","journal-title":"Nat Rev Neurol"},{"key":"1259_CR177","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/j.pain.0000000000001682","volume":"161","author":"I Skyt","year":"2020","unstructured":"Skyt I, Lunde SJ, Baastrup C, Svensson P, Jensen TS, Vase L (2020) Neurotransmitter systems involved in placebo and nocebo effects in healthy participants and patients with chronic pain: a systematic review. Pain 161:11\u201323","journal-title":"Pain"},{"key":"1259_CR178","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/brain\/awl008","volume":"129","author":"MV Solbrig","year":"2006","unstructured":"Solbrig MV, Adrian R, Baratta J, Lauterborn JC, Koob GF (2006) Kappa opioid control of seizures produced by a virus in an animal model. Brain 129:642\u2013654","journal-title":"Brain"},{"key":"1259_CR179","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1002\/jnr.24977","volume":"99","author":"A Sood","year":"2021","unstructured":"Sood A, Preeti K, Fernandes V, Khatri DK, Singh SB (2021) Glia: a major player in glutamate-gaba dysregulation-mediated neurodegeneration. J Neurosci Res 99:3148\u20133189","journal-title":"J Neurosci Res"},{"key":"1259_CR180","doi-asserted-by":"crossref","first-page":"736978","DOI":"10.3389\/fmed.2021.736978","volume":"8","author":"E Srinivasan","year":"2021","unstructured":"Srinivasan E, Chandrasekhar G, Chandrasekar P, Anbarasu K, Vickram A, Karunakaran R, Rajasekaran R, Srikumar P (2021) Alpha-synuclein aggregation in Parkinson\u2019s disease. Front Med 8:736978","journal-title":"Front Med"},{"key":"1259_CR181","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/cne.10997","volume":"469","author":"RK Stumm","year":"2004","unstructured":"Stumm RK, Zhou C, Schulz S, H\u00f6llt V (2004) Neuronal types expressing \u03bc-and \u03b4-opioid receptor MRNA in the rat hippocampal formation. J Comp Neurol 469:107\u2013118","journal-title":"J Comp Neurol"},{"key":"1259_CR182","doi-asserted-by":"crossref","first-page":"E241","DOI":"10.1038\/mtna.2015.14","volume":"4","author":"M Takahashi","year":"2015","unstructured":"Takahashi M, Suzuki M, Fukuoka M, Fujikake N, Watanabe S, Murata M, Wada K, Nagai Y, Hohjoh H (2015) Normalization of overexpressed \u03b1-synuclein causing Parkinson\u2019s disease by a moderate gene silencing with rna interference. Mol Ther Nucleic Acids 4:E241","journal-title":"Mol Ther Nucleic Acids"},{"key":"1259_CR183","doi-asserted-by":"crossref","first-page":"15959","DOI":"10.3390\/ijms140815959","volume":"14","author":"X Tian","year":"2013","unstructured":"Tian X, Hua F, Sandhu HK, Chao D, Balboni G, Salvadori S, He X, Xia Y (2013) Effect of \u03b4-opioid receptor activation on BDNF-TRKB vs. TNF-\u03b1 in the mouse cortex exposed to prolonged hypoxia. Int J Mol Sci 14:15959\u201315976","journal-title":"Int J Mol Sci"},{"key":"1259_CR184","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s40263-021-00821-0","volume":"35","author":"L Toll","year":"2021","unstructured":"Toll L, Cippitelli A, Ozawa A (2021) The NOP receptor system in neurological and psychiatric disorders: discrepancies, peculiarities and clinical progress in developing targeted therapies. CNS Drugs 35:591\u2013607","journal-title":"CNS Drugs"},{"key":"1259_CR185","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/ene.12883","volume":"23","author":"\u00d8 Torkildsen","year":"2016","unstructured":"Torkildsen \u00d8, Myhr KM, B\u00f8 L (2016) Disease-modifying treatments for multiple sclerosis\u2014a review of approved medications. Eur J Neurol 23:18\u201327","journal-title":"Eur J Neurol"},{"key":"1259_CR186","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41232-018-0086-5","volume":"38","author":"K Tsuboi","year":"2018","unstructured":"Tsuboi K, Uyama T, Okamoto Y, Ueda N (2018) Endocannabinoids and related N-acylethanolamines: biological activities and metabolism. Inflamm Regen 38:1\u201310","journal-title":"Inflamm Regen"},{"key":"1259_CR187","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/mds.10305","volume":"18","author":"D Twelves","year":"2003","unstructured":"Twelves D, Perkins KS, Counsell C (2003) Systematic review of incidence studies of Parkinson\u2019s disease. Mov Disord 18:19\u201331","journal-title":"Mov Disord"},{"key":"1259_CR188","doi-asserted-by":"crossref","first-page":"12956","DOI":"10.3390\/ijms222312956","volume":"22","author":"M Ubaldi","year":"2021","unstructured":"Ubaldi M, Cannella N, Borruto AM, Petrella M, Micioni Di Bonaventura MV, Soverchia L, Stopponi S, Weiss F, Cifani C, Ciccocioppo R (2021) Role of nociceptin\/orphanin FQ-NOP receptor system in the regulation of stress-related disorders. Int J Mol Sci 22:12956","journal-title":"Int J Mol Sci"},{"key":"1259_CR189","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0028-3908(99)00154-9","volume":"39","author":"EM Unterwald","year":"2000","unstructured":"Unterwald EM, Cuntapay M (2000) Dopamine-opioid interactions in the rat striatum: a modulatory role for dopamine D1 receptors in delta opioid receptor-mediated signal transduction. Neuropharmacology 39:372\u2013381","journal-title":"Neuropharmacology"},{"key":"1259_CR190","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.tem.2018.03.001","volume":"29","author":"R Van Eenige","year":"2018","unstructured":"Van Eenige R, Van Der Stelt M, Rensen PC, Kooijman S (2018) Regulation of adipose tissue metabolism by the endocannabinoid system. Trends Endocrinol Metab 29:326\u2013337","journal-title":"Trends Endocrinol Metab"},{"key":"1259_CR191","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.2174\/13816128113199990434","volume":"20","author":"L Velayudhan","year":"2014","unstructured":"Velayudhan L, Van Diepen E, Marudkar M, Hands O, Suribhatla S, Prettyman R, Murray J, Baillon S, Bhattacharyya S (2014) Therapeutic potential of cannabinoids in neurodegenerative disorders: a selective review. Curr Pharm Des 20:2218\u20132230","journal-title":"Curr Pharm Des"},{"key":"1259_CR192","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1146\/annurev.biochem.73.011303.073940","volume":"73","author":"M Waldhoer","year":"2004","unstructured":"Waldhoer M, Bartlett SE, Whistler JL (2004) Opioid receptors. Ann Rev Biochem 73:953\u2013990","journal-title":"Ann Rev Biochem"},{"key":"1259_CR193","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2147\/JIR.S266995","volume":"13","author":"H Wang","year":"2020","unstructured":"Wang H, Zhang Y, Ma X, Wang W, Xu X, Huang M, Xu L, Shi H, Yuan T, Jiang W (2020) Spinal Tlr4\/P2x7 receptor-dependent Nlrp3 inflammasome activation contributes to the development of tolerance to morphine-induced antinociception. J Inflamm Res 13:571\u2013582","journal-title":"J Inflamm Res"},{"key":"1259_CR194","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-2094-7-30","volume":"7","author":"H Wilms","year":"2010","unstructured":"Wilms H, Sievers J, Rickert U, Rostami-Yazdi M, Mrowietz U, Lucius R (2010) Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1\u03b2, TNF-\u03b1 and IL-6 in an in-vitro model of brain inflammation. J Neuroinflammation 7:1\u20138","journal-title":"J Neuroinflammation"},{"key":"1259_CR195","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/cne.901940308","volume":"194","author":"CJ Wilson","year":"1980","unstructured":"Wilson CJ, Groves PM (1980) Fine structure and synaptic connections of the common spiny neuron of the rat neostriatum: a study employing intracellular injection of horseradish peroxidase. J Comp Neurol 194:599\u2013615","journal-title":"J Comp Neurol"},{"key":"1259_CR196","doi-asserted-by":"crossref","first-page":"106566","DOI":"10.1016\/j.phrs.2022.106566","volume":"187","author":"C Xiang","year":"2022","unstructured":"Xiang C, Li H, Tang W (2022) Targeting CSF-1r represents an effective strategy in modulating inflammatory diseases. Pharmacol Res 187:106566","journal-title":"Pharmacol Res"},{"key":"1259_CR197","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3390\/ijms17081179","volume":"17","author":"Y Xu","year":"2016","unstructured":"Xu Y, Zhi F, Shao N, Wang R, Yang Y, Xia Y (2016) Cytoprotection against hypoxic and\/or MPP+ injury: effect of \u03b4-opioid receptor activation on caspase 3. Int J Mol Sci 17:1179","journal-title":"Int J Mol Sci"},{"key":"1259_CR198","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fnagi.2020.00078","volume":"12","author":"S Yan","year":"2020","unstructured":"Yan S, Wei X, Jian W, Qin Y, Liu J, Zhu S, Jiang F, Lou H, Zhang B (2020) Pharmacological inhibition of HDAC6 attenuates NLRP3 inflammatory response and protects dopaminergic neurons in experimental models of Parkinson\u2019s disease. Front Aging Neurosci 12:78","journal-title":"Front Aging Neurosci"},{"key":"1259_CR199","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.brainres.2011.01.083","volume":"1383","author":"L Yang","year":"2011","unstructured":"Yang L, Wang H, Shah K, Karamyan VT, Abbruscato TJ (2011) Opioid receptor agonists reduce brain EDEMA in stroke. Brain Res 1383:307\u2013316","journal-title":"Brain Res"},{"key":"1259_CR200","doi-asserted-by":"crossref","first-page":"105651","DOI":"10.1016\/j.intimp.2019.05.036","volume":"75","author":"C Yang","year":"2019","unstructured":"Yang C, Mo Y, Xu E, Wen H, Wei R, Li S, Zheng J, Li W, Le B, Chen Y (2019) Astragaloside IV ameliorates motor deficits and dopaminergic neuron degeneration via inhibiting neuroinflammation and oxidative stress in a Parkinson\u2019s disease mouse model. Int Immunopharmacol 75:105651","journal-title":"Int Immunopharmacol"},{"key":"1259_CR201","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000511979","volume":"4","author":"E Yarar","year":"2021","unstructured":"Yarar E (2021) Role and function of endocannabinoid system in major depressive disease. Med Cannabis Cannabinoids 4:1\u201312","journal-title":"Med Cannabis Cannabinoids"},{"key":"1259_CR202","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.brainres.2008.11.030","volume":"1252","author":"M Zhu","year":"2009","unstructured":"Zhu M, Li M-W, Tian X-S, Ou X-M, Zhu C-Q, Guo J-C (2009) Neuroprotective role of \u03b4-opioid receptors against mitochondrial respiratory chain injury. Brain Res 1252:183\u2013191","journal-title":"Brain Res"},{"key":"1259_CR203","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.neuint.2011.08.005","volume":"59","author":"M Zhu","year":"2011","unstructured":"Zhu M, Li M, Yang F, Ou X, Ren Q, Gao H, Zhu C, Guo J (2011) Mitochondrial ERK plays a key role in delta-opioid receptor neuroprotection against acute mitochondrial dysfunction. Neurochem Int 59:739\u2013748","journal-title":"Neurochem Int"},{"key":"1259_CR204","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10072-016-2757-9","volume":"38","author":"Z-G Zhu","year":"2017","unstructured":"Zhu Z-G, Sun M-X, Zhang W-L, Wang W-W, Jin Y-M, Xie C-L (2017) The efficacy and safety of coenzyme Q10 in Parkinson\u2019s disease: a meta-analysis of randomized controlled trials. Neurol Sci 38:215\u2013224","journal-title":"Neurol Sci"},{"key":"1259_CR205","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.pneurobio.2007.01.003","volume":"81","author":"C Zuccato","year":"2007","unstructured":"Zuccato C, Cattaneo E (2007) Role of brain-derived neurotrophic factor in Huntington\u2019s disease. Prog Neurobiol 81:294\u2013330","journal-title":"Prog Neurobiol"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-023-01259-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-023-01259-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-023-01259-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T07:28:08Z","timestamp":1689578888000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-023-01259-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":204,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1259"],"URL":"https:\/\/doi.org\/10.1007\/s10787-023-01259-0","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,15]]},"assertion":[{"value":"25 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable because this is a review paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors are agreed for the publication of current review paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}